lotto board best board on ihub
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TELK 4.27 X 4.29 now. dipping again.
CBPC heating up some bid building very tight now.
not sure i have a feeling i should have sold at 4.40 again.
TELK 4.25 RE ENTRY WOOO MON TELK!
im not too worried. maybe a bad .04 call. but these china plays are on fire lately. i think a close in the .037-.04 range would be great. a .04 break evern better!
WHACKERS!!!! .04 break and were GOLDEN IMO. but all these newbs scared from the chart! in above 4s all want out!
TELK dipping. re- entry possibility
yeah waht was ur past entry?
TELK was the play for me today. CBPC china play also. was looking great at .04 but tons of sellers being scared from ovve the weekend. if we get over .04 i think it could be ok? any opionions?
CBPC china play looking decent today. IMO alot of .04 sellers.. i think if we break through .04 we could be off to the races. anone esle?
very nice siix was watchng., was very suprised to see the multi day run!
TELKlooking for a dip!! i want re entry!!!
TELK WEEEEEEEEEE come on 5.00!!!!
TELK 4.09 X 4.10 now!!!
ooh i see. FDA approval is YEARS. im definetly not waiting for that! play the rumor sell on news for that bad boy!
TELK tryuing to bid build 3.96 X 4.00 now
not sure what you meant bud when you said the trial did not meet the endpoint. sum up in easier language lol? sorry bud new to premarket
TELK 3.95 X 4.00
GIGA 3.02 X 4.08
lets finddddd the bottom. hopeing for a repeat of the huge nasd loser last week?
thanks alot SL i will do
MEMY down 48% premarket anyone? not much volume or trades but still ?
TELK now 4.04X4.10 wheres this one going? crazy premarket!
hey bud GIGA and TELK im in TELK for today bud. up HUGE premarket already how about you?
well, while you grab the coffe. ill post some news!
I-many Signs Top Five Global Generics Pharmaceutical Company
Global Generics Organization Further Extends I-many's Reach in the Pharmaceutical Marketplace
EDISON, N.J., Oct 15, 2007 (BUSINESS WIRE) -- I-many, Inc. (NASDAQ:IMNY), a leading provider of contract management software and services for the enterprise, today announced a top five global generics pharmaceutical company has licensed I-many's recently introduced I-many CARS(R) NG solution. This industry-leading company is yet another new customer for I-many since I-many CARS NG was introduced on June 20th of this year. This now brings the total of major pharmaceutical companies who have licensed one or more of I-many's new generation solutions to 26, which includes 16 generic companies committed to I-many solutions.
I-many CARS NG is an industry leading system for managing rebate contracts and chargebacks for the life sciences industry, and a key module in the I-many Contract Management Suite for Life Sciences. With I-many CARS NG, clients receive insight into various complex financial components, reducing the possibility of rebate and chargeback overpayments, duplicate payments, and incorrect payments to ineligible parties. In addition to providing core functions for contract management, I-many CARS NG can be extended to include processing capabilities for prescription-level validation, direct-sale rebates, chargebacks and formulary management.
"As pharmaceutical contracts continue to increase in volume and complexity, life science organizations worldwide are increasingly looking for an integrated contract management solution that can manage complexity and drive insight from an integrated data set," said David Blumberg, executive vice president of fulfillment services at I-many. "I-many's solutions are designed to deliver this insight and minimize compliance risks. Another major pharmaceutical company has now recognized the many benefits of I-many's unique contract management solutions and we welcome them to our growing customer roster of leading pharmaceutical organizations."
John Rade, president and CEO of I-many added, "I-many's leadership in the life sciences industry is clearly demonstrated by the fact that an estimated 95 percent of all prescriptions filled in the U.S. pass through an I-many system. We are excited that yet another industry-leading pharmaceutical company has extended their commitment to I-many and our uniquely powerful I-many Contract Management Suite for Life Sciences solutions."
About I-many Contract Management Suite for Life Sciences(TM)
The core modules of the I-many Contract Management Suite for Life Sciences include several solutions specifically developed to handle the industry's most pressing issues. All the modules are built on a common foundation, I-many's ECMF, which combines enterprise-class security, robust and scalable J2EE platforms and an industry-standard database aligned in a true service-oriented architecture (SOA). Because I-many's ECMF allows all information, including metadata and documents, to be stored, accessed and managed using a common infrastructure across all its modules, the solution enables users to capture data once and use it repeatedly across the enterprise.
The I-many Contract Management Suite for Life Sciences includes I-many Contract Authoring(TM), I-many CARS(R) NG, I-many Medicaid Rebates(TM), I-many Government Pricing(TM), I-many Validata(TM), I-many Medicaid Analytics(TM), and I-many CARS(R) BI.
About I-many(R)
I-many (NASDAQ:IMNY) is the leading provider of contract management software and services for the enterprise. With more than 280 customers across 21 industries worldwide, I-many is enabling businesses to manage the entire contract lifecycle, from pre-contract processes and contract management to active compliance and contract optimization. The result is an end-to-end solution that provides enterprises with greater levels of insight into contract performance, allowing companies to improve profitability and achieve measurable return on investment. For more information, please visit www.imany.com.
This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include: the risk of unforeseen technical or practical impediments to planned software development and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE: I-many, Inc.
CONTACT: Media:
Text 100
Barbara DeConto, 415-593-8425
barbarad@text100.com
or
I-many, Inc.
Dennis Wong, 650-226-1535
dwong@imany.com
Copyright Business Wire 2007
yep got myself some green tea ready for the day! lets make some money!
TELK + GIGA premarket. anyone buying these 2. im new to microcap and trying to get a feel here?
Gmorinin SL how are you today?
me too siix. GL to you, maybe well see another gapper like last week ;)
lol alright i will tty guys n gals later. i will put this one on watch for sure. dart has been on fire with charts lately. promised CEQI and we got it. lets see if he pulls it off again!
ive been in CEQI with you now for a while. i will be sure to put USBL on watch tomorow.
yep. last week defiently was loving the china plays. see you all tomorow
i hope so. ill gut it out down here with the pennies/small caps get some capital then maybe move on and pull in the big $$ over at the lantern board!
haha belle dont you always bring your humor along? EXPECIALLY after a few cocktails. is that you bringing them in by the way? do i hear something? [Suppressed Sound Link]
WOOF the big dog is here. and hes in!
some nice action here friday. very nice.
LOL feel better sue!
soungs good to me spec. pretty soon ill be startin that job lol!
gnite all see you all tonorrow bright and early!
spec. come back to PENNYLAND